Summary
We estimated antagonist activity of metoprolol, pindolol, and propranolol in elderly cardiovascular patients by determining the extent to which the drugs occupied rabbit lung beta1- and rat reticulocyte beta2-adrenoceptors in plasma samples during drug treatment. The randomized, double-blind, crossover study was carried out by administering twice daily 100 mg metoprolol, 5 mg pindolol, and 80 mg propranolol for 7 days to 20 hypertensive subjects with a mean age of about 70 years. A 2-week interval was kept between administration of the different regimens. Receptor occupancy was measured at 1 hour before and 2 hours after administration of the last dose of each regimen by adding rabbit lung beta1- and rat reticulocyte beta2-receptors to plasma samples and by labeling the receptors with a radiolabeled beta-antagonist, (−)-[3H]CGP-12177. The results and conclusions were the following: (a) The extent to which metoprolol, pindolol, and propranolol occupied rabbit lung beta1-and rat reticulocyte beta2-adrenoceptors in plasma samples estimated accurately the intensity of beta-receptor antagonism in the patients who did not tolerate physiological and pharmacological tests measuring the degree of beta1- and beta2-adrenoceptor blockade. (b) The mean beta1- and beta2-receptor occupancy of pindolol and propranolol varied between 76% and 99% during the treatments. The mean beta1-receptor occupancy of the metoprolol regimen varied between 54% and 92%, and its beta2-receptor occupancy varied between 6% and 38%. Thus the antagonist activity of the metoprolol regimen differed significantly from that of the other regimens (ANOVA for repeated measures, p<0.05 and 0.001, for the beta1- and beta2-occupancy, respectively). (c) The extent of beta1- and beta2-receptor occupancy in plasma samples was in conformity with the literature on the intensity, selectivity, and duration of beta-blockade after similar drug doses. (d) The data on the receptor occupancy of beta-blocking drugs in plasma samples appear to be valuable in analyzing their effects, and it may be a method for optimizing drug therapy for aged cardiovascular patients.
Similar content being viewed by others
References
Wikstrand J, Berglund G. Antihypertensive treatment with beta-blockers in patients over 65.Br Med J 1982;285:850.
George CF. The rationale of treating high blood pressure in the elderly.Age Ageing 1979;8:110–114.
Tregaskis BF, McDevitt DG. Beta-adrenoceptor-blocking drugs in the elderly.J Cardiovasc Pharmacol 1990;16:S25-S28.
Amery A, Hansson L, Gudbrandsson T, Siverstson R, Svensson A. Hypertension in the elderly.Acta Med Scand 1981;210:221–229.
Kannel WB, Gordon T. Evaluation of cardiovascular risks in the elderly. The Framingham Study Bull.NY Acad Med 1978:54:573–591.
McDevitt DG. The assessment of beta-adrenoceptor blocking drugs in man.Br J Clin Pharmacol 1977;4:415–425.
McDevitt DG. In vivo studies on the function of cardiac beta-adrenoceptors in man.Eur Heart J 1989;10(Suppl B):22–28.
Koch-Weser J. Metoprolol.N Engl J Med 1979;301:698–703.
Frishman WH. Pindolol.N Engl J Med 1983;308:940–944.
Shand DG. Propranolol.N Engl J Med 1975;293:280–285.
Wellstein A, Palm D, Belz GG, Pitschner HF. Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction on clinical effects of β-blockers.Arzneim Forsch/Drug Res 1985;35:2–6.
Wellstein A, Palm D, Belz G-G, Butzer R, Polsak R, Pett B. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy.Eur Heart J 1987;8(Suppl M):3–8.
Rochester CL, Gammon DE, Shane E, et al. A radioreceptor assay for propranolol and 4-hydroxypropranolol.Clin Pharmacol Ther 1980;28:32–39.
Brodde O-E, Kuhlhoff F, Arroyo J, Prywarra A. No evidence for temperature-dependent changes in the pharmacological specificity of β1- and β2-adrenoceptors in rabbit lung membranes.Naunyn Schmiedebergs Arch Pharmacol 1983;322:20–28.
Pauwels PJ, Gommeren W, Van Lommen G, Janssen PAJ, Leysen JE. The receptor binding profile of the new antihypertensive agent Nebivolol and its stereoisomers compared with various β-adrenergic blockers.Mol Pharmacol 1988;34:843–851.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent.J Biol Chem 1951;193:265–275.
Kaiser G, Wiemer G, Kremer G, Dietz J, Palm D. Identification and quantification of beta-adrenoceptor sites in red blood cells from rats.Naunyn Schmiedeberg's Arch Pharmacol 1978;305:41–50.
Wellstein A, Palm D, Wiemer G, Schäfer-Korting M, Mutschler E. Simple and reliable radioreceptor assay for beta-adrenoreceptor antagonists and active metabolites in native human plasma.Eur J Clin Pharmacol 1984;27:545–553.
Kaila T. A sensitive radioligand binding assay for timolol.J Pharm Sci 1991;80:296–299.
Staehelin M, Simons P, Jaeggi K, Wigger N. CGP-12177: A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells.J Biol Chem 1983;258:3496–3502.
Scatchard G. The attractions of proteins for small molecules and ions.Ann NY Acad Sci 1949;51:660–672.
O'Donnell SR, Wanstall JC. Evidence that ICI 118,551 is a potent highly selective beta-2 adrenoceptor antagonist and can be used to characterize beta-adrenoceptor populations in tissues.Life Sci 1980;27:671–677.
Munson PJ, Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand-binding systems.Anal Biochem 1980;107:220–239.
McPherson GA. Analysis of radioligand binding experiments. A collection of micro computer programs for the IBM PC.J Pharmacol Methods 1985;14:213–228.
Wellstein A, Palm D, Pitcshner HF, Belz GG. Receptor-binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.Eur J Clin Pharmacol 1985;29:131–147.
Williams LT, Lefkowitz RJ. Theory of ligand-receptor interactions. In:Radioligand Binding Studies in Adrenergic Pharmacology. New York: Raven Press, 1978:27–41.
Juberg EN, Minneman KP, Abel PW. β1- and β2-receptor binding and functional response in right and left atria of the rat heart.Naunyn Schmiedeberg's Arch Pharmacol 1985;330:193–198.
Brown EM, Fedak SA, Woodard CJ, Aurbach GD, Rodbard D. Beta adrenergic receptor interactions. Direct comparison of receptor interaction and biological activity.J Biol Chem 1976;251:1239–1246.
Kaila T, Karhuvaara S, Huupponen R, Iisalo E. The analysis of plasma kinetics and β-receptor binding and -blocking activity of timolol following its small intravenous dose.Int J Clin Pharmacol Ther Tox 1993;31:351–354.
Walle UK, Walle T, Bai SA, Olanoff LS. Stereoselective binding of propranolol to human alpha-1-acid glycoproteins and albumin:Clin Pharmacol Ther 1983;34:718–723.
Fitzgerald JD, O'Donnell SR. Pharmacology of 4-OH-propranolol, a metabolite of propranolol.Br J Pharmacol 1971;43:222–235.
Von Bahr CD, Hermansson J, Tawara K. Plasma levels of (+) and (−) propranolol and 4-hydroxypropranolol after administration of racemic (±)-propranolol in man.Br J Clin Pharmacol 1982;14:79–82.
Brodde O-E, Daul A, Wellstein A, Palm D, Michel MC, Beckeringh JJ. Differentiation of beta-1 and beta-2 adrenoceptor-mediated effects in humans.Am J Physiol 1988;254:H199-H206.
Lucker P, Moore G, Wieselgren I, Olofsson B, Bergstrand R. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily and with conventional tablets once daily and divided doses.J Clin Pharmacol 1990;30:S17-S27.
Benfield P, Clissold SP, Brogden RN, Metoprolol: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischemic heart disease and related cardiovascular disorders.Drugs 1986;31:376–429.
Kaila T, Iisalo E. Selectivity of acebutolol, atenolol and metoprolol in healthy volunteers estimated by the extent the drugs occupy β2-receptors in the circulating plasma.J Clin Pharm 1993;33(10).
Kendall M, Akhlagli S, Hughhes B, Lewis H. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol?J Clin Pharmacol 1990;30:S98-S102.
Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine-metabolizers.Clin Pharmacol Ther 1983;34:732–737.
Regårdh C-G, Landahl S, Larsson M, et al. Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, nonsmoking, elderly individuals.Eur J Clin Pharmacol 1983;24:221–226.
Regårdh C-G. Summary of session I.J Clin Pharmacol 1990;30:S55-S56.
Aellig WH. Clinical pharmacology of pindolol.Am Heart J 1982;104:346–356.
Gretzer I, Alvan G, Duner H, Garle M, Sjöquist F. Beta-blocking effects of pindolol in young and elderly hypertensive patients.Eur J Clin Pharmacol 1986;31:415–418.
Routledge PA, Shand DG. Clinical pharmacokinetics of propranolol.Clin Pharmacokinet 1979;4:73–90.
Cruickshank JM, Prichard BNC. Kinetics of individual beta-blockers. Lipophilic, liver-metabolized beta-blockers. Propranolol. In: Cruickshank JM, Prichard BNC, eds.Beta-Blockers in Clinical Practice. London: Churchill Livingstone, 1988:214–223.
Wood AJJ, Feely J. Pharmacokinetic drug interactions with propranolol.Clin Pharmacokinet 1983;8:253–262.
Lemaire M, Tillement JP. The binding characteristics of some adrenergic beta-receptor antagonists to human serum proteins.Biochem Pharmacol 1982;31:359–365.
Hawksworth GM, Betts T, Crowe A, et al. Diazepam/beta-adrenoceptor antagonist interactions.Br J Clin Pharmacol 1984;17(Suppl 1):69S-76S.
Kaila T, Marttila R. Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.Br J Clin Pharmacol 1993;35:507–515.
Brodde O-E, Zerkowski H-R, Borst HG, Maier W, Michel MC. Drug- and disease-induced changes of human cardiac β1- and β2-adrenoceptors.Eur Heart J 1989;10(Suppl B):38–44.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaila, T., Iisalo, E., Lehtonen, A. et al. Extent of beta1- and beta2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly. Cardiovasc Drug Ther 7, 839–849 (1993). https://doi.org/10.1007/BF00877714
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00877714